Printer Friendly Version View printer-friendly version
<< Back
Mediclinic Intnl plc - Annual Financial Report
RNS Number : 2038S
Mediclinic International plc
22 June 2018
 

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company" or the "Group")

 

22 June 2018

 

POSTING OF ANNUAL REPORT AND FINANCIAL STATEMENTS,
NOTICE OF ANNUAL GENERAL MEETING AND PROXY FORM

 

Mediclinic announces that its Annual Report and Financial Statements in respect of the financial year ended 31 March 2018 ("2018 Annual Report") is being posted to shareholders today, together with the Notice of Annual General Meeting and the Form of Proxy in relation to the Company's annual general meeting to be held on Wednesday, 25 July 2018 at The Lincoln Centre, 18 Lincoln's Inn Fields, London WC2A 3ED at 15:00 (BST).

 

In accordance with Listing Rule 9.6.1, the above documents are being submitted to the UK Listing Authority via the National Storage Mechanism and will shortly be available to the public for inspection at www.morningstar.co.uk/uk/NSM.

 

The documents are also being made available on the Company's website at www.mediclinic.com during the course of today.

 

In accordance with DTR 6.3.5 of the FCA's Disclosure Guidance and Transparency Rules, additional information is set out in the appendices to this announcement. The information in the appendices are extracted from the 2018 Annual Report and should be read in conjunction with the Company's preliminary results announcement issued on 24 May 2018 (RNS number 0970P). This material is not a substitute for reading the full 2018 Annual Report.

 

About Mediclinic International plc

 

Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-based private healthcare group.

 

Mediclinic comprises 75 hospitals and 28 clinics. Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100 inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 22 clinics with more than 700 inpatient beds in the United Arab Emirates.

 

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.

 

For further information, please contact:

 

Company Secretary, Link Company Matters Limited

Jayne Meacham / Caroline Emmet

+44 (0)20 7954 9569

 

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

ir@mediclinic.com

+44 (0)20 3786 8181

 

Media queries

FTI Consulting

Brett Pollard/Debbie Scott - UK

+44 (0)20 3727 1000

Sherryn Schooling - South Africa

+27 (0)21 487 9000

 

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com 

Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd

 

 

APPENDIX A: PRINCIPAL RISKS AND UNCERTAINTIES

 

The Group's principal risks and uncertainties are detailed below, as extracted from pages 44 to 48 of the 2018 Annual Report. For further information, please refer to the 2018 Annual Report. 

 

PRINCIPAL RISK

MOVEMENT IN 2018

DESCRIPTION OF RISK

MITIGATION OF RISK

Economic

and business

environment risk

 

1

Increased

 

Economic growth in Switzerland and in South Africa continued to be weak, resulting in increased risk exposure.

The risk relates to the downturn in the general economic and business environment, including all those factors that affect a company's operations, customers, competitors, stakeholders, suppliers and industry trends.

 

The business environment risk includes the power of funders and the potential negative impact on tariffs and fees resulting from the shift of the relative negotiating power towards funders, away from healthcare service providers.

 







 





 

Systems to monitor developments in the economic and business environment of trends and early warning indicators

Proactive monitoring and negotiation by Group's funder relations departments

Focus on quality and continuum of care to reinforce the Company's position

Business investment and acquisition risks

 

1, 2

Reduced

 

The investments and governance processes were strengthened during the year.

This is the risk of increased financial exposure relating to major strategic business investments and acquisitions.


 


 


 

Strategic planning processes

Due diligence processes

Investment mandates

Board oversight

Post-acquisition management processes

 

Competition

 

1

No change

 

Healthcare providers market continued to grow through normal channels of acquisitions, expansions, new facilities etc. There were no major changes to impact risk exposure.

 

The risk relates to the uncertainty created by the existence of competitors or the emergence of new competitors with their own strategies.

 

The risk includes the outmigration of care, partly driven by further technological developments and the development of alternative

care models.



 

Proactive monitoring

Strategic planning processes

Quality and value of care processes

Availability and cost of capital (including financing and liquidity risk)

 

2

Increased

 

Interest rates are expected to rise in the year ahead, which may lead to an increase in the cost of capital.

These risks involve the cost, terms and availability of capital to finance strategic expansion opportunities and/or the refinancing or restructuring of existing debt which has been affected by prevailing capital market conditions.




 








 




 

Long-term planning of capital requirements and cash-flow forecasting

Scrutiny of cash-generating capacity within the Group

Proactive and long-term agreements with banks and other funders relating to funding facilities

Monitoring compliance with requirements of debt covenants

Further details on capital risk management and the Group's borrowings are contained in the annual financial statements

 

Operational and credit risks

 

2, 3

Reduced

 

The risk exposure was reduced following the successful integration of the Al Noor business.

Operational risk refers to diverse types of operational events with the potential for financial loss, operational interruptions or reputational damage.

 

Credit risk is the risk of loss due to a funder's inability to pay the outstanding balance owing, default by banks and/or other deposit-taking institutions, or the inability to recover outstanding amounts due from patients.




 



 


 




 




 




 


 

Preservation of a sound internal financial control environment

Effective operational risk management processes

Extensive combined assurance processes

Monitoring operations through key performance indicators ("KPIs")

Continuous enhancement of operational efficiency and cost reduction

Regulated minimum solvency requirements for funders

Monitoring approved funders

Treasury policy

Executive and board level oversight

 

Quality and

stability of

operational

services risk

 

3

No change

 

The operational services risk did not change significantly and remained stable throughout the year.

 

The risk refers to the quality of service and the stability of the operations. It includes but is not limited to:



 


 


 


 


 






 

Patient satisfaction surveys (internal and external)

Complaints monitoring

Training programmes

Supervising service levels

Emergency backup power generation

Emergency planning

Plans to deal with disasters

Extensive fire-fighting and detection systems, including comprehensive maintenance processes

Comprehensive insurance to deal with financial impact of potential disasters

 





 






 

incidents of poor service or incidents where operational management fails to respond effectively to complaints;

operational interruptions which refers to any disruption of the facility and may include the threat of disrupted power or water supply; and

fire and allied perils causing damage or business interruption.

Information

Systems security

and availability

risk

 

4

Increased

 

The increased risk relates to the continued external threats arising from cyberattack.

Information systems security risk (including cyber risk) relates to unauthorised access to information systems, failure of data integrity and confidentiality. Availability risk relates to instances where systems are not available for use by its intended users.

 

Project delivery risk, closely associated with information systems risk, refers to issues or occurrences that could potentially interfere with completion of projects, including scope, timeliness and appropriateness of delivery.

 





 


 


 


 


 

Comprehensive information systems logical access, change and physical access controls

Disaster recovery planning

System design and architecture

Group ICT Security Committee

Experienced project management teams

Proactive monitoring and oversight

Regulatory and compliance risk

 

5

Increased

 

The increased risk relates to the introduction of new regulations which includes

TARMED (Tariff

System for Outpatient Medical Services) in Switzerland and the EU General Data Protection Regulation ("GDPR").

The risk involves adverse changes in laws and regulations impacting the Group or failure to comply with laws and regulations which may result in losses, fines, prosecution or damage to reputation.

 

The risk includes ethical and governance risks that refer to the unexpected negative consequences of unethical actions or the failure of the control and oversight mechanisms which were designed and implemented to uphold the ethical standards and controls of the organisation.




 





 



 













 






 


 




 


 

Proactive engagement strategies with stakeholders

Health policy units created to conduct research and provide strategic input into reform processes

Active industry participation across all divisions

Company Secretarial and/or Legal departments support operational management, monitor regulatory developments and, where necessary, obtain expert legal advice for the effective implementation of compliance initiatives

Compliance risks identified and assessed as part of compliance management processes

Visible ethical leadership

Monitoring and investigation of incidents reported on the ethics line

Executive and Board level oversight

 

Clinical risks

 

6

No change

 

Clinical processes

across operating

divisions continued to be

a key focus area

for the Group.

Risk exposure

remained at a

comparable level

to the previous

year.

Clinical risks are associated with the provision of clinical care and may result in undesirable quality of care or clinical outcomes.

 

The risks include a pandemic and disease outbreak. A pandemic is an epidemic of infectious disease that spreads through human populations across a large region. Disease outbreak involves highly infectious diseases with a high mortality rate.

 

Such risks may also result in damage to the Mediclinic brand equity, which is the value of the Group's brand names.

 






 



 


 


 



 




 



 


 



 

Refer to the Clinical Services Report for a detailed analysis of the strategies to manage and monitor clinical risks

A Group-wide clinical risk registers per operating division

Accreditation processes

Clinical governance processes

Monitoring clinical performance indicators

Comprehensive processes for infection control and prevention

Marketing and communication strategies

Quality management processes

Stakeholder engagement and disclosure strategies

 

Risk of availability, recruitment and retention of skilled resources and medical practitioners

 

7

No change

 

Vacancies and turnover ratios in respect of skilled resources and medical practitioners are expected to remain at similar levels to the prior year.

The availability and support of admitting doctors, whether independent or employed, are critical to the services the Group provides.

 

There is a shortage of skilled labour, particularly a shortage of qualified and experienced

nursing staff in Southern Africa.




 





 






 









 

 

Monitoring doctor satisfaction, movement and doctors' profiles

Details on the relationship with doctors are provided in the Sustainable Development Report

The employment, recruitment and retention strategies are explained in the Sustainable Development Report

The extensive training and skills development programme, and the foreign recruitment programme are further explained in the Sustainable Development Report.

 

           

 

KEY

 

REFERENCE

CATEGORY

BUSINESS PROCESSES

STRATEGIC PRIORITIES

1

Strategic and business environment


 

Strategy formulation and implementation

Strategic investments and strategic projects

 


 

Delivering business value

Continuing to expand as a successful international healthcare group

2

Financial and reporting risks


 

Revenue cycle

Procure to pay cycle

Financial management and control

Treasury

Health information (including coding)

 

3

Operational risks


 

Infrastructure

Marketing and corporate communication

Operations

 

4

Information technology risks



 

Information and communications technology ("ICT")

ICT projects

 

5

Regulatory compliance risks


 

Legal and secretarial

Governance, risk and compliance

Environmental management

 


 

Ensuring good corporate governance

Acting as a responsible corporate citizen

6

Clinical risks

Clinical

Nursing

Pharmacy

Coding

 


 

Delivering superior value to its patients

Delivering integrated healthcare in collaboration with doctors and allied healthcare professional communities

 

 

People risks

Human resources

Compensation and benefits cycle


 



 

Being an employer of choice

Having constructive relationships with all stakeholders

Being a valued member of the community

 

Increased

 

Risk exposure increased due to change in business environment, increased investments, increased dependency of operations on information technology, information sensitivity and cost involved.

 

Reduced

Proactive and continuous monitoring, favourable results of negotiations, effective treasury and risk management processes resulted in lowering of risk exposure.

 

No change

Risk exposure has not changed significantly as the operating and regulatory environment has remained mostly the same and enhanced risk mitigation measures have kept the risk at same level.

 

 

 

APPENDIX B: STATEMENT OF DIRECTORS' RESPONSIBILITIES

 

The Statement of Directors' Responsibilities below is extracted from page 160 of the 2018 Annual Report. This statement relates solely to the 2018 Annual Report and is not connected to the information presented in this announcement or the preliminary results announcement released on 24 May 2018.

 

The Directors are responsible for preparing the Annual Report, including the financial statements, in accordance with applicable law and regulation.

 

The UK Companies Act requires the Directors to prepare financial statements for each financial year. The Directors prepared the Group and Company financial statements in accordance with International Financial Reporting Standards ("IFRS"), as adopted by the European Union. The Directors should only approve the financial statements if they are satisfied that they give a true and fair view of the state of affairs of the Group and Company and of the profit or loss of the Group and Company for the reporting period. In preparing the financial statements, the Directors are required to:

 

select suitable accounting policies and apply them consistently;

 

state whether applicable IFRS have been followed, subject to any material departures disclosed and explained in the financial statements;

 

make judgements and accounting estimates that are reasonable and prudent; and

 

prepare the financial statements on the going-concern basis, unless it is inappropriate to presume that the Group and Company will continue in business.

 

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Group's and Company's transactions and disclose with reasonable accuracy, at any time, the financial position of the Group and Company and enable them to ensure that the financial statements and the Directors' Remuneration Report comply with the UK Companies Act and, in respect of the Group's consolidated financial statements, Article 4 of the IAS Regulation.

 

The Directors are responsible for safeguarding the assets of the Group and Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

 

The Directors are responsible for the maintenance and integrity of the financial and associated corporate information published on the Company's website at www.mediclinic.com. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

 

The Directors consider that the Annual Report and Financial Statements, taken as a whole, is fair, balanced and understandable and provides the information necessary for shareholders to assess the Group and Company's performance, business model and strategy.

 

Each of the Directors, whose names and functions are listed on pages 86 to 89 of the Annual Report, confirm that to the best of their knowledge:

 

the Group and Company financial statements, which were prepared in accordance with IFRS, as adopted by the European Union, give a true and fair view of the assets, liabilities, financial position and profit of the Group; and

 

the Strategic Report includes a fair review of the development and performance of the business and the position of the Group and the Company, together with a description of the principal risks and uncertainties that it faces.

 

DISCLOSURE OF INFORMATION TO AUDITORS

 

Each of the directors confirms that:

 

to the best of their knowledge and belief, there is no relevant audit information of which the Company's auditors are unaware; and

 

they have taken all reasonable steps to ascertain any relevant audit information and to establish that the Company's auditors are aware of that information.

 

 

APPENDIX C: RELATED PARTY TRANSACTIONS

 

The following description of related party transactions involving the Company and is subsidiaries during the financial year ended 31 March 2018 is extracted from page 241 of the 2018 Annual Report.

 

33.

RELATED PARTY TRANSACTIONS

 

Remgro Limited owns, through various subsidiaries (Remgro Healthcare (Pty) Ltd, Remgro Health Ltd and Remgro Jersey GBP Ltd) 44.56% (2017: 44.56%) of the Company's issued share capital.

 

 

The following transactions were carried out with related parties:

 

 

 

2018

£'m

2017

£'m

 

 

 

 

 

 

 

 

i)

Transactions with shareholders

 

 

 

Remgro Management Services Limited (subsidiary of Remgro Ltd)

 

 

 

  Managerial and administration fees

0.3

0.3

 

  Internal audit services

0.2

0.2

 

 

 

 

 

V & R Management Services AG (subsidiary of Remgro Ltd)

 

 

 

  Administration fees*

-

-

 

 

 

 

ii)

Key management compensation

 

 

 

Key management includes the directors (executive and non-executive) and members of the executive committee.

 

 

 

Salaries and other short-term benefits

 

 

 

  Short-term benefits

6

6

 

  Post-employment benefits*

-

-

 

  Share-based payment

1

1

 

 

 

 

iii)

Transactions with associates

 

 

 

Zentrallabor Zürich

 

 

 

  Fees earned

(2)

(1)

 

  Purchases

8

10

 

 

 

 

 

Spire Healthcare Group plc

 

 

 

  Non-executive director fee*                                                 

-

-

 

 

 

 

 

Wits University Donald Gordon Medical Centre (Pty) Ltd

 

 

 

  Fees paid

 

* Amount is less than £0.5m.

2

2

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACSSEWFMFFASEEM

IMPORTANT DISCLAIMER

ACCESS TO THIS AREA OF THE WEBSITE MAY BE RESTRICTED UNDER SECURITIES LAWS, RULES OR REGULATIONS IN CERTAIN JURISDICTIONS. THIS NOTICE REQUIRES YOU TO CONFIRM CERTAIN MATTERS (INCLUDING THAT YOU ARE NOT RESIDENT OR PHYSICALLY PRESENT IN SUCH A JURISDICTION), BEFORE YOU MAY OBTAIN ACCESS TO THE INFORMATION ON THIS AREA OF THE WEBSITE. THESE MATERIALS ARE NOT DIRECTED AT OR TO BE ACCESSED BY, OR DISTRIBUTED OR DISSEMINATED TO, DIRECTLY OR INDIRECTLY, PERSONS RESIDENT OR PHYSICALLY LOCATED IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS, RULES OR REGULATIONS OF THAT JURISDICTION OR WOULD RESULT IN A REQUIREMENT TO COMPLY WITH CONSENT OR OTHER FORMALITY WHICH MEDICLINIC REGARDS AS UNDULY ONEROUS.

Combination of Mediclinic International Limited ("Mediclinic") and Al Noor Hospitals Group plc ("Al Noor") (the "Combination")

Access to the website

You are attempting to enter the part of the website that is designated for the publication of documents and information in connection with the Combination.

If you would like to view this part of the website, please read this notice carefully. This notice applies to all persons who view this part of the website and, depending on where you are located, may affect your rights or responsibilities. Mediclinic reserves the right to amend or update this notice at any time and you should, therefore, read it in full each time you visit the site. In addition, the contents of this part of the website may be amended at any time, in whole or in part, at the sole discretion of Mediclinic.

This part of the website contains electronic versions of materials relating to the Combination. The materials you are seeking to access are made available in good faith and for information purposes only and are subject to the terms and conditions set out below. Any person seeking to access this part of the website represents and warrants to Mediclinic that they are doing so for information purposes only.

To allow you to view information about the Combination, you must read this notice and then click "I ACCEPT". If you are unable to agree, you should click "I DECLINE" and you will not be able to view information about the Combination.

The Combination would be made by means of a scheme document to be published by Mediclinic which would contain the full terms and conditions of such Combination, including details on how it may be accepted. Any decision made in relation to the Combination should be made solely and only on the basis of the information provided in any such document.

Overseas jurisdictions

Viewing the materials you are seeking to access may be restricted under securities laws in certain jurisdictions. All persons who wish to view this part of the website must first satisfy themselves that they are not subject to any local requirements which prohibit or restrict them from doing so and should inform themselves about, and observe, any legal or regulatory requirements applicable in their jurisdiction.

These materials are not directed at or intended to be accessible by persons resident in any jurisdiction if to do so would constitute a violation of the relevant laws or regulations of that jurisdiction.

YOU SHOULD NOT, DIRECTLY OR INDIRECTLY, DOWNLOAD, MAIL, FORWARD, DISTRIBUTE, SEND OR SHARE THE INFORMATION OR DOCUMENTS CONTAINED ON THIS PART OF THE WEBSITE TO ANY PERSON. IN PARTICULAR, YOU SHOULD NOT, DIRECTLY OR INDIRECTLY, MAIL, FORWARD, DISTRIBUTE OR SEND THE INFORMATION OR DOCUMENTS CONTAINED THEREIN TO ANY JURISDICTION WHERE IT WOULD BE UNLAWFUL TO DO SO. MEDICLINIC AND ITS ADVISERS DO NOT ASSUME ANY LIABILITY FOR ANY VIOLATION BY ANY PERSON OF ANY OF THESE RESTRICTIONS.

It is your responsibility to satisfy yourself as to the full observance of any relevant laws and regulatory requirements. If you are in any doubt, you should click on “I DECLINE” below and exit this webpage.

Cautionary Note Regarding Forward-Looking Statements

This part of the website and the information contained in it may contain certain forward-looking statements with respect to the financial condition, results of operations and businesses of Mediclinic and the Mediclinic Group (being Mediclinic and its subsidiaries and subsidiary undertakings) and Al Noor and the Al Noor Group (being Al Noor and its subsidiaries and subsidiary undertakings) following the Combination. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements include, among other things, statements concerning the potential exposure of Mediclinic and the Mediclinic Group to market risks and statements expressing management's expectations, beliefs, estimates, forecasts, projections and assumptions, including as to future potential cost savings, synergies, earnings, cash flow and prospects. These forward-looking statements are identified by their use of terms and phrases such as "anticipate", "believe", "could", "estimate", "expect", "goals", "intend", "may", "objectives", "outlook", "plan", "probably", "project", "risks", "seek", "should", "target", "will" and similar terms and phrases. There are a number of factors that could affect the future operations of Mediclinic and the Mediclinic Group and Al Noor and the Al Noor Group post Combination and could cause those results to differ materially from those expressed in the forward-looking statements included in this part of the website. All forward-looking statements contained in this part of the website are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Each forward-looking statement speaks only as at the specified date of the relevant document within which the statement is contained. None of Mediclinic, the Mediclinic Group, Al Noor or the Al Noor Group undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information. In light of these risks, results could differ materially from those stated, implied or inferred from the forward-looking statements contained in this part of the website.

Responsibility

In relation to any Combination-related materials accessible on this area of the website please note any statement of responsibility contained therein.

The documents included in this part of the website issued or published by Mediclinic speak only at the specified date of the relevant document and Mediclinic has, and accepts, no responsibility or duty to update or revise such documents.

In relation to any such announcements or other Combination-related materials issued or published by Al Noor, or which relate to Al Noor and the Al Noor Group, that are accessible on this website, the only responsibility accepted by Mediclinic and its directors is for the correctness and fairness of its reproduction.

Neither the directors of Mediclinic, nor Mediclinic, nor any of their affiliated companies, have reviewed, and no such person is or shall be responsible for or accepts any liability in respect of, any information contained on any other website which may be linked to or from this part of the website.

Other

If you are in any doubt about the contents of this part of the website or the action you should take, you should seek your own financial advice from an appropriately authorised independent financial adviser.

This notice shall be governed by and construed in accordance with English law.

CONFIRMATION OF UNDERSTANDING AND ACCEPTANCE

If you are not able to give these confirmations, you should click on “I DECLINE” below and exit the webpage.